Level D· Scientific groundwork from lab and animal studiesAnimal StudyEurope PMCOpen access

AB102. Therapeutic potential of adipose-derived stem cells-based micro-tissues in a rat model of stress urinary incontinence

Animal Study with a reported sample of 3, published in Transl Androl Urol (2016) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Transl Androl Urol (2016)
Reported sample size
3
Source database
Europe PMC
PMCID
PMC4842705

Abstract (original English)

Objective Traditional two-dimensional (2D) cell culture of adipose-derived stem cells (ADSCs) to halt stress urinary incontinence (SUI) progression have low retention rate and limited function recuperation poorly mimicking in vivo conditions. This study aims to examine the potential and mechanism of three-dimensional (3D) cultures of ADSCs in the treatment of SUI in a rat model simulating childbirth injury. Methods ADSCs were used to generate microtissues (MTs) with a hanging drop method. A total of 48 postpartum Sprague-Dawley rats were developed SUI models by 4 hours vagina dilation (VD) followed by bilateral ovariectomy (OV). Ten rats underwent sham OV without VD served as control group. The SUI rats were divided into three groups and received urethral injection of PBS, ADSCs and MTs. Specimens were harvested for histology examination and ADSCs tracking at day 1, 3, 7, 28 (n=3) post-injection. At day 28, the remaining rats were examined for voiding function. Western blot, immunofluorescence and immunohistochemistry staining were performed to examine histological changes and cytokines expression. Results The voiding function and histopathological structures were better recovered in MTs group than those in ADSCs group. Compared with ADSCs, MTs express higher level of vascular endothelia growth factor (VEGF), TNFα stimulated gene/protein 6 (TSG-6) in vitro and represented a hig

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.